rottlerin

an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);

Also Known As:

Networked: 160 relevant articles (10 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Maioli, Emanuela: 7 articles (11/2019 - 06/2009)
2.	Hou, Yingying: 7 articles (01/2018 - 01/2016)
3.	Valacchi, Giuseppe: 6 articles (11/2019 - 06/2009)
4.	Wang, Lixia: 6 articles (01/2018 - 01/2016)
5.	Wang, Zhiwei: 6 articles (01/2018 - 01/2016)
6.	Zhou, Xiuxia: 6 articles (01/2018 - 01/2016)
7.	Maioli, E: 5 articles (01/2018 - 03/2008)
8.	Valacchi, G: 5 articles (01/2018 - 03/2008)
9.	Zhao, Zhe: 5 articles (09/2017 - 01/2016)
10.	Kwon, Taeg Kyu: 5 articles (04/2012 - 11/2008)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2018 - "Various studies have discussed the antitumor properties of rottlerin in human malignancies. " 01/01/2018 - "The present study investigated whether rottlerin has a tumor suppressive role via inhibiting the expression of TAZ, using cell viability assay, apoptosis and cell cycle analyses, western blot analysis and Tanswell invasion assay. " 09/22/2017 - "Recent studies have revealed that rottlerin is a natural chemical drug to exert its anti-cancer activity. " 01/31/2017 - "In the current study, we aimed to explore whether rottlerin inhibits the expression of TAZ in NSCLC, leading to its anti-cancer activity. " 10/25/2016 - "Although further studies revealed that rottlerin regulated multiple signaling pathways to suppress tumor cell growth, the exact molecular insight on rottlerin-mediated tumor inhibition is not fully elucidated. "
2.	Glioma (Gliomas) 12/01/2006 - "Because our initial studies of this agent in a series of glioma cell lines showed only partial growth inhibition at clinically achievable concentrations, we questioned whether inhibition of PKC signaling using the PKC-delta inhibitor rottlerin might potentiate therapeutic efficacy. " 10/25/2016 - "In the current study, we determine the function of rottlerin on glioma cell growth, apoptosis, cell cycle, migration and invasion. " 10/25/2016 - "Therefore, down-regulation of Cdc20 by rottlerin could be a promising therapeutic strategy for the treatment of glioma." 10/25/2016 - "We observed that rottlerin significantly inhibited the expression of Cdc20 in glioma cells, implying that Cdc20 could be a novel target of rottlerin. " 10/25/2016 - "Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells."
3.	Prostatic Neoplasms (Prostate Cancer) 01/01/2018 - "Our findings indicated that rottlerin might be a potential therapeutic compound for treating patients with prostate cancer." 01/01/2018 - "Moreover, overexpression of EZH2 abrogated the rottlerin-induced inhibition of cell growth, migration, and invasion in prostate cancer cells. " 01/01/2018 - "Importantly, we defined that rottlerin decreased the expression of EZH2 and H3K27me3 in prostate cancer cells. " 01/01/2018 - "We found that rottlerin treatment led to inhibition of cell growth, migration and invasion, but induction of apoptosis in prostate cancer cells. " 01/01/2018 - "Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer."
4.	Hypoxia (Hypoxemia) 12/01/2010 - "The aim of this study was to examine the effects of chronic intermittent hypoxia (CIH; 7,000 m, 8 h/day) and acute administration of PKC-δ inhibitor (rottlerin, 0.3 mg/kg) on the expression and subcellular distribution of PKC-δ and PKC-ε in the left ventricular myocardium of adult male Wistar rats by Western blot and quantitative immunofluorescence microscopy. " 12/01/2010 - "Rottlerin partially reversed the hypoxia-induced increase in PKC-δ in the mitochondrial fraction. " 01/14/2010 - "Conversely, rottlerin, a specific PKCdelta inhibitor, exacerbated BBB hyperpermeability and tight junction (TJ) disruption during aglycemic hypoxia, indicating a protective role of PKCdelta against aglycemic hypoxia-induced BBB hyperpermeability. " 08/01/2004 - "When H9c2 cells were pretreated with PKC-delta inhibitor rottlerin (3 microM), hypoxia-induced apoptotic and necrotic cell death were significantly increased. " 04/01/2005 - "Rottlerin attenuated the infarct size-limiting effect of chronic hypoxia (P < 0.05), and it had no effect in controls. "
5.	Ischemia 09/01/2008 - "The present study was designed to investigate the modulatory effects of rottlerin on ischemia reperfusion induced myocardial injury. " 09/01/2008 - "Rottlerin, a selective PKCdelta inhibitor, did not modulate ischemia-reperfusion (I/R) induced myocardial injury at low dose (3 microM). " 01/01/2002 - "Therefore, we utilized the PKC-delta selective antagonist, rottlerin, to assess the effect of inhibition of this isozyme on cardioprotection induced by one-cycle of IPC prior to 30 minutes of ischemia and 2 hours of reperfusion. " 04/01/2005 - "The PKC inhibitors chelerythrine (1 or 5 mg/kg) or rottlerin (selective for PKC-delta isoform; 0.3 mg/kg) were administered intravenously as a single bolus 15 min before ischemia. " 09/01/2007 - "DADLE reduced infarct size after 35 min of ischemia followed by 2 h of reperfusion by 69%, and PKC-epsilon-TIP and rottlerin eliminated 48% and 63%, respectively, of the infarct size-limiting effect of DADLE. "

Related Drugs and Biologics

1.	Genistein
2.	Protein Kinase C
3.	Phosphotransferases (Kinase)
4.	Polyphenols
5.	Protein Kinases (Protein Kinase)
6.	Wortmannin
7.	Protein Kinase C-epsilon
8.	Leucine-2-Alanine Enkephalin (Enkephalin, Leucine 2 Alanine)
9.	Tyrosine (L-Tyrosine)
10.	Free Radicals

Related Therapies and Procedures

1.	Therapeutics
2.	Chemoprevention
3.	Punctures
4.	Ligation
5.	Intraperitoneal Injections